We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Non-Invasive Blood Test Detects Synovial Signatures in Rheumatoid Arthritis Patients

By LabMedica International staff writers
Posted on 23 Nov 2023
Print article
Image: A new study marks the first blood-based detection of synovial signatures (Photo courtesy of 123RF)
Image: A new study marks the first blood-based detection of synovial signatures (Photo courtesy of 123RF)

Rheumatoid arthritis (RA), a severe chronic inflammatory condition, impacts millions of individuals globally. Patients often have to try multiple therapies from among the 20+ FDA-approved drugs across six categories before finding an effective one. Traditionally, identifying synovial signatures in RA patients required an invasive biopsy. Now, a breakthrough non-invasive blood test offers a more efficient method for patients to discover the most suitable treatment.

Aqtual, Inc. (Hayward, CA, USA) has demonstrated that its pioneering platform is capable of detecting synovial gene expression signatures in RA patients through a simple blood test. The study represents the first instance of identifying synovial signatures via a blood-based method. The research demonstrated the platform's ability to detect synovial transcriptomic signatures in blood plasma, distinguishing RA molecular signatures from other inflammatory disorders.

The technology utilized by Aqtual's platform involves analyzing cell-free DNA (cfDNA) in a single blood sample to measure both epigenetics and transcriptomics. This approach allows for a comprehensive, real-time analysis of the disease and its treatment response, offering an advantage over traditional cfDNA methods. Aqtual recently initiated a proof-of-concept clinical trial to assess the platform's effectiveness in guiding the choice of treatment for RA patients. The study involved 191 participants, including 89 with rheumatoid arthritis, 29 healthy controls, 61 with various inflammatory conditions, and 12 with osteoarthritis. The results from Aqtual's platform showed a 96.1% specificity and 90.8% sensitivity in identifying synovial signatures in RA patients.

"Our goal is to reduce the gap between precision medicine and practical clinical solutions for chronic conditions, starting with RA," said Diana Abdueva, PhD, CEO and founder of Aqtual. "Our test will help guide clinicians in treatment choices, improving patient outcomes and reducing costs. This study is a significant step, and we look forward to further validating our platform."

Related Links:
Aqtual, Inc. 

Gold Member
Troponin T QC
Troponin T Quality Control
Verification Panels for Assay Development & QC
Seroconversion Panels
New
C-Reactive Protein Assay
OneStep C-Reactive Protein (CRP) RapiCard InstaTest
New
Cytomegalovirus Test
NovaLisa Cytomegalovirus (CMV) IgG Test

Print article

Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more